graph EGM comparisons
durvalumab alonetitledurvalumab plus osimertinibtitleStandard of Care (SoC)titleosimertinibtitleplacebotitlePACIFIC, 2017 NCT02125461 laNSCLC - M - all population 476/237MYSTIC (D ; all population), 2020 NCT02453282 mNSCLC - L1 - all population 374/372MYSTIC (D ; PDL1>25%), 2020 NCT02453282 mNSCLC - L1 - PDL1 positive 163/162CAURAL (EXPLORATORY), 2019 NCT02454933 mNSCLC - L2 - EGFR mutant 14/15ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 NCT02352948 mNSCLC - L2 - PDL1 positive 62/64

Pathology:  laNSCLC - M - all population;   mNSCLC - L1 - all population;   mNSCLC - L1 - PDL1 positive;   mNSCLC - L2 - EGFR mutant;   mNSCLC - L2 - PDL1 positive; 

laNSCLC - M - all populationmNSCLC - L1 - all populationmNSCLC - L1 - PDL1 positivemNSCLC - L2 - EGFR mutantmNSCLC - L2 - PDL1 positive
PACIFIC, 2017MYSTIC (D ; all population), 2020MYSTIC (D ; PDL1>25%), 2020CAURAL (EXPLORATORY), 2019ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020
durvalumab alone4T1T1T1T1
durvalumab plus osimertinib1T1
Standard of Care (SoC)0T0T0T0
osimertinib0T0
placebo0T0